



PRODUCT: **GAVRETO® (pralsetinib)**

COMPANY: Blueprint Medicines

THERAPEUTIC AREA & INDICATION:  
Treatment of lung cancer

---

#### ABOUT THE PRODUCT

GAVRETO® (pralsetinib) is a kinase inhibitor approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA approved test, adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy, and adults and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). For more information, including important prescribing information, visit [GAVRETO.com](http://GAVRETO.com).